PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|24|3875-3882

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.24, 2014-05, pp. : 3875-3882

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

By Dancey Janet E.  

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1125-1138

Adis International

Access to resources Recommend Favorite

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

Thymidylate synthase inhibitors for non-small cell lung cancer

By Galvani Elena   Peters Godefridus J   Giovannetti Elisa  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1343-1356

Informa Healthcare

Access to resources Recommend Favorite

Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 17, Iss. 6, 2016-05 ,pp. : 739-745

Bentham Science Publishers

Access to resources Recommend Favorite

Selective Cyclooxygenase-2 Inhibitors and Non-small Cell Lung Cancer

By  

Current Medicinal Chemistry, Vol. 9, Iss. 21, 2002-11 ,pp. : 1851-1858

Bentham Science Publishers

Access to resources Recommend Favorite